Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 6/20 | 0.92 |
| ▸ | CXCR2 | P25025 | 14/20 | 0.68 |
| ▸ | CXCR1 | P25024 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12260594 | 0.96 | CCR6 (1.00) | CCR6CXCR2CXCR1 | |
| SCHEMBL12260593 | 0.95 | CCR6 (0.98) | CCR6CXCR2CXCR1 | |
| SCHEMBL12087223 | 0.82 | CCR6 (0.76) | CCR6CXCR2 | |
| SCHEMBL12570024 | 0.81 | CXCR2 (1.00) | CCR6CXCR2CXCR1 | |
| SCHEMBL20761033 | 0.81 | CCR6 (0.72) | CCR6CXCR2CXCR1 | |
| SCHEMBL14450153 | 0.80 | CCR6 (0.61) | CCR6CXCR2CXCR1 | |
| SCHEMBL13197595 | 0.79 | CXCR2 (0.76) | CCR6CXCR2CXCR1 | |
| SCHEMBL14310580 | 0.78 | CXCR2 (0.76) | CCR6CXCR2CXCR1 | |
| SCHEMBL12260597 | 0.78 | CCR6 (0.67) | CCR6CXCR2CXCR1 | |
| SCHEMBL12262520 | 0.78 | CXCR2 (0.93) | CCR6CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588092-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | claimed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | claimed |
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-09-05 | — | — | US | disclosed |
| EP-2588092-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | Galderma Research & Development (FR) | 2013-05-08 | — | — | EP | disclosed |
| EP-1485089-B1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | MERCK SHARP & DOHME (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-1539678-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1, 2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012001076-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-01-05 | — | — | WO | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1818325-B1 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORP (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231393-A1 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA | AQP3, SUCNR1, AQP1 | CCR6 3148/4885CXCR2 3127/4885CXCR1 1617/4885 |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | CXCR3, ACKR3, CCL11 | CCR6 13/4885CXCR2 6/4885CXCR1 5/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | CCR6 19/4885CXCR2 7/4885CXCR1 3/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CCR6 19/4885CXCR2 7/4885CXCR1 3/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | CCR6 19/4885CXCR2 7/4885CXCR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.